The Yangtze River broke out!

Medical Network News on March 9 A few days ago, Yangtze River 4 generic drugs lansoprazole for injection was approved for production and deemed to have been reviewed
.
At present, the company has 55 products that have been reviewed (20 are the first), leading the injection review list; 87 new products under review are "watching" over 70 billion markets, and 22 varieties have not been approved for the first imitation, of which 11 varieties Exclusively by Yangtze River/the first company to report production under the new classification; 12 innovative drugs were unveiled, and the first class of gynecological new drugs will be launched soon
.

55 Ge over commentary varieties Pa screen, leading injections over assessment standings
as of March 3, 473 varieties of existing enterprises through or as if through conformance evaluation, from evaluation through business situation, Qilu Pharmaceutical lead to over 58 varieties comment , Yangtze River and China Biopharmaceuticals tied for second place with 55 over-reviewed products
.

Figure: The number of over-rated varieties of TOP5 companies Mi Nei.
com data show that among the 55 over-evaluated varieties in Yangtze River, 20 varieties were the first to be reviewed, including raltitrexed for injection, mecobalamin injection, and cefoxitin sodium for injection , Entecavir oral liquid, epalrestat tablets, tamoxifen citrate tablets, terazosin hydrochloride capsules and other varieties are exclusive reviews
.
Table 1: Yangtze River's reviewed varieties Source: Meinenet MED2.
0 Chinese drug review database.
From the perspective of dosage form, 20 of Yangtze River's reviewed varieties are injections (7 were the first to review), leading the injection review list; From the perspective of the treatment field, 55 categories cover 11 treatment categories, focusing on the two major therapeutic areas of systemic anti-infective drugs (13 categories), anti-tumor and immunomodulators (8 categories)
.
The rich over-reviewed varieties have made Yangtze River a fruitful harvest in the national collection
.
In the fourth batch of centralized procurement that opened the bid a few days ago, Yangzijiang has 8 varieties selected, including propofol medium/long-chain fat emulsion injection, ambroxol hydrochloride injection, levofloxacin tablets, doxofylline injection, hyaluronic acid Sodium eye drops are the company's newly approved listing products after 2020
.
Public in Chinese cities in the first half of 2020In the terminal competition pattern of hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions for short), Yangtze River has a low or zero market share in these eight major varieties.
Now it has successfully won the bid.
Quickly seize the market
.
Relying on the comprehensive advantages of large enterprises, Yangtze River is actively deploying the consistency evaluation of generic drugs.
With thenormalized development ofmass procurement , especially the increase in the proportion of injections in the future, the company's advantages in centralized procurement will be further revealed
.

　　87 new products are focusing on the market of over 70 billion yuan, 22 varieties are the first to be imitated.

On February 21, Yangzijiang first submitted an application for the marketing of brivaracetam injection with imitation 3 types
.
No generic drugs have been approved for this product.
At present, the company has 107 products under the new registration classification, covering 12 major therapeutic categories, focusing on two major therapeutic areas: neurological drugs (21 varieties) and systemic anti-infective drugs (21 varieties)
.
According to data from Mi Nei.
com, the market size of terminal systemic anti-infective drugs and neurological drugs in public medical institutions in China exceeded 200 billion yuan and 100 billion yuan respectively in 2019
.
Among the 107 new classified product categories, 20 have been approved for production and deemed to have passed the consistency evaluation.
Among them, dexmedetomidine hydrochloride injection and levofloxacin eye drops were the first to have been reviewed.
Entecavir oral solution and raeti for injection Qusai has an exclusive review
.
In 2019, the total sales of the 87 varieties under review in China's public medical institutions exceeded 70 billion yuan, of which 22 have not yet been approved for the first imitation (including the first imitation of the dosage form) in the domestic market
.
Table 2: Yangtze River is reviewing and there is no first copy-approved variety Source: Meinenet MED2.
0 Chinese Drug Evaluation Database Lurasidone and Shugenglucose are heavy varieties exceeding $1 billion
.
Lurasidone is an atypical (second-generation) antipsychotic drug with global sales of 194.
2 billion yen in 2020.
The original product was approved for import in January 2019; Shugengluconate is the world's first specific binding Neuromuscular blockade antagonist drugs, global sales in 2020 reached 1.
198 billion U.
S.
dollars, the original research product was approved for import in May 2017, and the sales growth rate in China's public medical institutions in the first half of 2020 was 117.
5%
.
11 varieties are the first or exclusive to report production by Yangtze River under new classification, including brivaracetam injection, tedizolamide phosphate for injection, rupatadine fumarate oral liquid, neconazole hydrochloride cream, methanesulfonic acid Safinamide sheet, Ringer's dextrose injection sodium acetate, sodium potassium, magnesium and oral solutions and the like
.

　　Twelve innovative drugs are under development, and new gynecological category 1 drugs are on the market soon.

In terms of R&D and innovation, Yangzijiang currently has 12 innovative drugs applied for clinical or clinical trials.
The fastest research and development progress is the first category of new drug Levoornidazole Phosphate Disodium for Injection , The product was applied for listing in August 2019, and was included in the priority review on the grounds of “innovative drugs with obvious therapeutic advantages” in November of the same year.
It is currently in the first round of data release and will be launched soon
.
Levoornidazole Disodium Phosphate for Injection is a nitroimidazole antibiotic used to treat gynecological pelvic inflammatory diseases .
It is the sodium salt of ornidazole levorotary isomer phosphate derivative and is a marketed Levoornidazole Prodrug
.
According to data from Meinenet, the sales of terminal ornidazole and levornidazole in China's public medical institutions exceeded 3 billion yuan and 200 million yuan respectively in 2019
.
Table 3: Yangtze River’s key innovative drugs under research.
Source: Meinenet.
com China Drug Clinical Trial Announcement Library.
Uknafil Hydrochloride Tablets is a PDE-5 inhibitor developed by Jilin University.
Tasly applies for clinical trials.
Yangtze River conducts clinical research for use Treatment of erectile dysfunction, phase III clinical trials are currently underway
.
YZJ-1139 tablets are highly effective antagonists of orexin 1 and 2 dual receptors, which can improve sleep by inhibiting orexin receptors
.
The Phase II clinical trial has been completed .
4 new class 1 drugs are undergoing phase I clinical trials
.
YZJ-0673 maleate tablet is a pan-PI3K inhibitor for advanced malignant solid tumors .
No drug with the same target has been approved for marketing in China; YZJ-0318 maleate tablet is the third representative skin growth factor ( EGFR-TKI) receptor inhibitors can selectively inhibit T790M resistance mutations
.
Source: Mi Nei.
com database Note: Statistics are as of March 3, if there are any omissions, please correct me!